Systemic ALCL portends a better prognosis than non-ALCL PTCL [20–23], and within the ALCL subpopulation, those that are ALK-1 positive have a better prognosis than those that are ALK-1 negative (5-year OS, 70% versus 49%) [5]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.